Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. - Wikidata - wikimedia - TriplyDB

Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

http://www.wikidata.org/entity/Q37745182

about

Raf family kinases: old dogs have learned new tricks Therapeutic Implications of Targeting AKT Signaling in Melanoma Tailoring the Treatment of Melanoma: Implications for Personalized Medicine A High-Throughput, Multi-Cell Phenotype Assay for the Identification of Novel Inhibitors of Chemotaxis/Migration.Adapt, Recycle, and Move on: Proteostasis and Trafficking Mechanisms in Melanoma Drug delivery nanoparticles in skin cancers Regulation and function of TPL-2, an IκB kinase-regulated MAP kinase kinase kinase Integrative modelling of the influence of MAPK network on cancer cell fate decision Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Integrated analysis of multidimensional omics data on cutaneous melanoma prognosis.TANDEM: a two-stage approach to maximize interpretability of drug response models based on multiple molecular data types.Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation.Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines.Novel somatic mutations to PI3K pathway genes in metastatic melanoma Multiple signal pathways in obesity-associated cancer.Biology of Barrett's esophagus and esophageal adenocarcinoma AKT family and miRNAs expression in IL-2 induced CD4(+)T cells.Targeting multiple key signaling pathways in melanoma using leelamine.Targeting sphingosine kinase-1 to inhibit melanoma.Butein inhibits metastatic behavior in mouse melanoma cells through VEGF expression and translation-dependent signaling pathway regulation.MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway.The Akt signaling pathway: an emerging therapeutic target in malignant melanoma.Loss of MiR-664 Expression Enhances Cutaneous Malignant Melanoma Proliferation by Upregulating PLP2 Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy A Unique High-Throughput Assay to Identify Novel Small Molecule Inhibitors of Chemotaxis and Migration.A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling Functional effects of GRM1 suppression in human melanoma cells.Lymphadenectomy promotes tumor growth and cancer cell dissemination in the spontaneous RET mouse model of human uveal melanoma.Collections of simultaneously altered genes as biomarkers of cancer cell drug response Association between functional polymorphisms in genes involved in the MAPK signaling pathways and cutaneous melanoma risk Follow-up analysis of a randomized phase III immunotherapeutic clinical trial on melanoma.SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression SHP2 phosphatase as a novel therapeutic target for melanoma treatment.Advances in melanoma senescence and potential clinical application.Targeting BRAF in advanced melanoma: a first step toward manageable disease.Novel therapies in melanoma.Narrowing the knowledge gaps for melanoma Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies.

P2860

Q24316181-DB45B907-C592-4DD0-A619-B03B5C91A614 Q24631438-8B63CC19-6029-464B-8D97-0810DF7EBC12 Q26775806-01CFE936-8657-4B84-8EF4-1F868146DDA3 Q27335903-580265CE-C2EE-4C1B-A1FB-ECEE5357B770 Q28069018-1FA0E2CD-F9CE-4986-8E6B-A9C1E4ED724D Q28390405-C09392BD-60CB-4A91-AB95-827558C6978F Q28392677-3A037E08-C544-419F-8A8D-8CD5B9543207 Q28534949-E365A21B-205A-471F-BA06-6A664DB3007D Q28601717-D9C4B39C-8C76-44C2-8EA3-ECDC2FC6CEA5 Q31089944-3FA4A2E6-9744-4CB1-9377-5DDAFC70F9A2 Q31126284-251E8B87-C694-4880-8E1B-BD523A8584FE Q33569998-F17FF4BE-A2A7-4EC3-8446-4D4F342D66EF Q33755862-BBD3A9B6-3903-4656-96A6-9DD5E9185BD6 Q34159519-48B3A0BC-6603-4EC1-8469-E67FB68E7209 Q34220097-7F86716B-7C6C-46B6-84C2-98AAF0ECB3C2 Q34389570-F964B581-D0D3-4362-A5DB-9FCFFC598D65 Q34633750-0E4D278E-2699-4F68-8975-90528CD14238 Q34644324-A49EF1CE-CF9A-4A8E-BCB9-6CAF314AF2C4 Q35083572-BC447CD8-DCD7-4746-BF90-40B60F8A0912 Q35136450-2B505FEE-DA3E-4A0D-B508-25630FDF2AA0 Q35789935-1CBCCA27-C08A-4315-BDC5-5246660EFE67 Q35875431-93F708DE-1149-4D5E-9414-EB29B44FE088 Q35907425-6A07C1C8-064E-4D05-AD5A-701761155B61 Q35911227-0EE5ACF3-C3AF-40D1-B0BE-88AF5DABD2BF Q36194074-1348E067-EF0A-4BE8-B9A9-B6FC96B3FB03 Q36278239-AFEC6F88-997F-4580-9FFE-7AF895D10B57 Q36296349-76A8B161-50F5-4034-8758-724F09486914 Q36384334-ADCA528C-C199-43A7-BC36-40DADD5D2A50 Q36409682-0095482B-C4B2-4091-975C-3300401D893F Q36689098-569236E9-AD09-4509-B273-9A27CDF26EA1 Q36698868-C815D53B-C7FC-443B-8E9B-E9964FDF658F Q36740729-B6A9DCB0-79B0-4C60-8E42-2A7CDB839E9C Q37560757-1B5D185F-DDA5-4F5D-827E-F56425393446 Q37581437-C4A7C2A4-20C9-4DB4-AE47-3E47F5335EC2 Q37687479-FE1D5FB6-5D06-4C26-BDB7-E6177B249937 Q37818577-60CB1C73-33B8-435B-B451-875B55FF7628 Q37859164-172416F9-F343-4DF2-9636-298A552C750B Q37957141-786E4A2A-7D8F-4092-9FEC-FF245CED9EBE Q37984547-5E474C78-4F8C-4B22-A0E8-BA751FD485DB Q37992693-FCC1D1A3-B628-4EA2-882D-BF82349E2641

P2860

Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

http://www.wikidata.org/entity/Q37745182

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 May 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

@en

Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

@nl

type

label

Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

@en

Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

@nl

prefLabel

Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

@en

Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

@nl

P1433

Q37745182-E15F05CC-BE7E-4F54-8B37-F5F22522E3FA

P1476

Q37745182-DE412841-51E9-4186-8929-E3ADB49A076D

P2093

Q37745182-1BB6BAF5-9E59-4F13-A0B8-8CE6A42606F5

Q37745182-C6CFF03A-792A-4924-8E6F-61CA72FB268B

Q37745182-F4C318BC-74D3-4FCD-9DBB-A66449D7DDEB

P2860

Q37745182-035FF71D-2CF9-4577-93E7-BDAF61B4001B

Q37745182-05A04DA4-16BA-475D-A4D3-5CA65C58E9E1

Q37745182-0829EB91-F1F9-4AE9-96B7-4169C091BC2A

Q37745182-09ED503C-7E79-4C43-9FB5-6554A5EBC7B3

Q37745182-0FA03F10-D558-4F17-8D84-39057208FC91

Q37745182-102DCE79-F53F-4BBE-B4C5-FAAA0E04924B

Q37745182-15A1B6E1-7EB7-4218-B642-75D1198E707B

Q37745182-17B864BD-B38E-40B1-AFDB-1CEE66EFC29D

Q37745182-185D85F3-85BC-44BF-B1EE-365387DDDA36

Q37745182-1B0F782A-F84D-4062-A183-06B648FBF083

P304

Q37745182-2E0CDE92-CF55-4D0D-9F5E-5BD92D7EAFB0

P31

Q37745182-8B2E299C-739F-4509-9E28-1ED6055C519D

P356

Q37745182-A72BA36E-B6DD-4ECF-BF20-99668D5B93C0

P407

Q37745182-EF79883E-D26A-455E-9113-ABFB7E4A4391

P433

Q37745182-0231DD30-CDB0-48C3-9A3E-64D56F4F0B38

P478

Q37745182-E30B4443-3CC3-4418-85E5-FADF28F390DC

P577

Q37745182-8481BA47-A5DB-4FCB-8E50-2B6443728864

P698

Q37745182-AE6F0EAB-6155-45EC-9B26-969EF7FF200A

P932

Q37745182-89FED46A-0A33-4460-8605-C92997231DE5

P356

J.BCP.2010.04.029

P1433

Biochemical Pharmacology

P1476

Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

@en

P2093

Gajanan S Inamdar

http://www.w3.org/2001/XMLSchema#string

Gavin P Robertson

http://www.w3.org/2001/XMLSchema#string

SubbaRao V Madhunapantula

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Rewired ERK-JNK signaling pathways in melanoma

Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

MEK1 mutations confer resistance to MEK and B-RAF inhibition.

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

Mutations of the BRAF gene in human cancer

P304

624-637

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BCP.2010.04.029

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

80

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20450891

http://www.w3.org/2001/XMLSchema#string

P932

2897908

http://www.w3.org/2001/XMLSchema#string